Highlight
The PRISM randomized controlled trial in Chinese patients aged 18-50 with young-onset non–type 1 diabetes demonstrated that a technology-enhanced, precision medicine approach integrating autoantibody testing, C-peptide measurements, and genetic profiling combined with algorithm-based treatment significantly improved cardiometabolic targets and proxies of β-cell function as well as reduced emotional distress. However, this intensified intervention did not reduce the incidence or progression of diabetes-related complications after three years compared with standard clinic care.
Background
Young-onset type 2 diabetes (YOD), defined as onset before age 40, represents a growing global health burden characterized by more aggressive disease progression, earlier development of complications, and heterogeneous etiologies including autoimmunity and monogenic forms. These complexities challenge traditional clinical approaches that classify diabetes primarily by clinical phenotype. Given the diversity in pathophysiology and treatment response, precision medicine strategies aiming to tailor management using biomarkers and genetic information have been proposed to improve outcomes. However, high-quality evidence from randomized controlled trials assessing the long-term impact of such personalized approaches on clinical endpoints remains limited, especially in East Asian populations where genetic and metabolic profiles differ from Western cohorts. The Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) study addresses this gap by evaluating the efficacy of an integrated biomarker-guided care model in a contemporary cohort of Chinese patients with young-onset diabetes.
Study Design
The PRISM study was a single-center, randomized controlled trial conducted from 2020 to 2021 enrolling 884 Chinese adults aged 18 to 50 who were diagnosed with non–type 1 diabetes at or before age 40. Participants were randomized to either an intervention group receiving the Joint Asia Diabetes Evaluation (JADE)-PRISM program or a control group receiving usual care (JADE only). The JADE-PRISM intervention comprised a technology-assisted comprehensive assessment including measurement of pancreatic autoantibodies, fasting and stimulated C-peptide levels to assess β-cell function, and genetic screening for both common variants associated with type 2 diabetes and rare monogenic diabetes mutations. This was followed by an intensive, algorithm-based treatment period lasting one year and subsequent annual evaluations by an endocrinologist-led multidisciplinary team over two additional years. Primary outcome was a composite of incident or progression of all diabetes-related complications at three years. Secondary outcomes included achievement of at least three of five predefined treatment targets (HbA1c <6.2%, blood pressure <120/75 mmHg, LDL cholesterol <1.2 mmol/L, triglycerides <1.2 mmol/L, and reduced waist circumference), changes in β-cell function proxies, and patient-reported outcome measures (PROMs) including emotional distress.
Key Findings
The trial randomized 441 participants to the JADE-PRISM group and 443 to the JADE-only group, with mean age 40.7 years and mean diagnosis age 32.5 years. Baseline characteristics showed substantial metabolic derangements and complications: 699 participants presented with central obesity, 669 with dyslipidemia, 588 with hypertension, and 313 with albuminuria. Autoantibody positivity was noted in 46 participants, monogenic diabetes mutations in 23, and 82 had markedly reduced C-peptide levels (<200 pmol/L). Insulin therapy was required in 250 participants.
Over the three-year follow-up, the primary composite endpoint of diabetes-related complications occurred in 26.3% of the intervention group versus 28.2% of controls, a difference not reaching statistical significance (OR 0.908; 95% CI 0.675–1.221). In contrast, the intervention group showed significant improvements in secondary outcomes: 23.8% achieved three or more treatment targets compared to 12.2% in the control group (P < 0.001). Markers indicative of β-cell function improved, suggesting preservation or recovery of endogenous insulin secretion capacity with individualized therapy. Additionally, participants in the JADE-PRISM arm reported reduced emotional distress measured by PROMs, highlighting better psychological wellbeing aligned with enhanced personalized care.
Importantly, no significant safety concerns were reported, and the study demonstrated feasibility and acceptability of integrating biomarker and genetic data into routine clinical management for YOD in a resource-efficient manner.
Expert Commentary
The PRISM trial represents a landmark effort to implement precision medicine in a large cohort of young-onset diabetics in Asia, providing essential proof-of-concept evidence that biomarker-guided, multidisciplinary care pathways can improve metabolic control and patient quality of life. The lack of demonstrated reduction in complications within three years is not unexpected given the complex natural history of diabetes and the relatively short follow-up for micro- and macrovascular outcomes, which generally evolve over longer durations. It underscores the need for longer-term studies to evaluate whether early personalized interventions translate into sustained clinical benefit.
The detailed phenotyping incorporating pancreatic autoimmunity and monogenic diabetes screening is a notable advancement addressing the heterogeneity inherent in YOD, allowing more precise classification and targeted therapy. For example, identifying monogenic forms enables the use of specific oral agents or dose adjustments differing from standard type 2 diabetes regimens, while autoantibody status informs the risk for progression to insulin dependence.
Limitations include the single-center design and restriction to a Chinese population, which may affect generalizability to diverse ethnic groups. Additionally, the reliance on combined composite endpoints may dilute individual complication signals; further in-depth analyses of specific complications such as retinopathy or nephropathy are awaited. Continued optimization of algorithms incorporating emerging biomarkers and integration with digital health tools could further enhance precision care effectiveness.
Conclusion
The PRISM randomized controlled trial demonstrates that a precision medicine approach employing comprehensive biogenetic profiling and multidisciplinary algorithm-based treatment substantially improves cardiometabolic targets, β-cell functional proxies, and patient-reported distress in young-onset diabetes. However, these benefits did not translate into reduced diabetes-related complications over the three-year follow-up period. These findings highlight the potential for precision medicine to refine diabetes classification and management but also emphasize the necessity for longer-term, multicenter studies to confirm impact on hard clinical outcomes and to inform broad implementation strategies.
Funding and Trial Registration
The PRISM study was supported by institutional and governmental research grants. The trial is registered under ClinicalTrials.gov with the identifier NCT042xxxx (please verify actual registration number upon dissemination).
References
1. Luk AOY, et al. Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes. Diabetes Care. 2026 Jul;49(7):1202-1212. PMID:42118608.
2. Lee R, et al. Characterizing young-onset type 2 diabetes: clinical features and glycemic control patterns. Diabetes Care. 2018;41(2):e12-e13.
3. Shepherd M, et al. Genetic testing for monogenic diabetes: clinical practice and challenges. Nat Rev Endocrinol. 2020;16(6):330-342.
4. World Health Organization. Global report on diabetes. Geneva, 2016.
5. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S98-S110.